| abstract |
modified tgf-beta2 antisense oligonucleotides, their use and pharmaceutical compositions comprising the same. the invention relates to an oligonucleotide consisting of 10 to 18 nucleotides from selected regions of the tgf-beta1, tgf-beta2 or tgf-beta3 nucleotide sequence, which comprises modified nucleotides such as modified lna, ena, oxide of polyalkylene-, 2'-fluoro, 2'-o-methoxy and/or 2'-o-methyl. the invention further relates to pharmaceutical compositions comprising such an oligonucleotide, in which the composition or oligonucleotide is used in the prevention and/or treatment of malignant and/or benign tumors, an immunological disease, fibrosis, or an ophthalmic disease, such as dry eye, glaucoma or posterior capsular opacification (pco). |